[go: up one dir, main page]

BRPI0412916A - formulações liofilizadas de cci-779 - Google Patents

formulações liofilizadas de cci-779

Info

Publication number
BRPI0412916A
BRPI0412916A BRPI0412916-4A BRPI0412916A BRPI0412916A BR PI0412916 A BRPI0412916 A BR PI0412916A BR PI0412916 A BRPI0412916 A BR PI0412916A BR PI0412916 A BRPI0412916 A BR PI0412916A
Authority
BR
Brazil
Prior art keywords
formulations
cci
lyophilized
methods
preparing
Prior art date
Application number
BRPI0412916-4A
Other languages
English (en)
Inventor
Joseph Thomas Rubino
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115376&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0412916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0412916A publication Critical patent/BRPI0412916A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"FORMULAçõES LIOFILIZADAS DE CCI-779". A presente invenção refere-se a formulações de CCI-779 liofilizadas e soluções úteis para preparar formulações de CCI-779 secas por congelamento compostas de CCI-779 e um solvente selecionado entre dimetilsuifóxido, acetonitrila, etanol, isopropanol ou álcool t-butílico. Também são proporcionados os métodos para preparar as formulações de CCI-779 liofilizadas, métodos de reconstituição das mesmas e aplicações para as mesmas.
BRPI0412916-4A 2003-07-25 2004-07-15 formulações liofilizadas de cci-779 BRPI0412916A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49029303P 2003-07-25 2003-07-25
PCT/US2004/023773 WO2005011688A1 (en) 2003-07-25 2004-07-15 Cci-779 lyophilized formulations

Publications (1)

Publication Number Publication Date
BRPI0412916A true BRPI0412916A (pt) 2006-09-26

Family

ID=34115376

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412916-4A BRPI0412916A (pt) 2003-07-25 2004-07-15 formulações liofilizadas de cci-779

Country Status (20)

Country Link
US (1) US20050020615A1 (pt)
EP (1) EP1648454A1 (pt)
JP (1) JP2007500191A (pt)
KR (1) KR20060052880A (pt)
CN (1) CN1829514A (pt)
AR (1) AR045094A1 (pt)
AU (1) AU2004261163A1 (pt)
BR (1) BRPI0412916A (pt)
CA (1) CA2532251A1 (pt)
CO (1) CO5680425A2 (pt)
CR (1) CR8153A (pt)
EC (1) ECSP066394A (pt)
IL (1) IL172573A0 (pt)
MX (1) MXPA05013865A (pt)
NO (1) NO20056178L (pt)
RU (1) RU2345772C2 (pt)
SG (1) SG144165A1 (pt)
TW (1) TW200505501A (pt)
WO (1) WO2005011688A1 (pt)
ZA (1) ZA200600684B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI307277B (en) 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
EP1701698B1 (en) * 2004-01-08 2008-01-16 Wyeth a Corporation of the State of Delaware Directly compressible pharmaceutical composition for the oral admimistration of cci-779
EP1781672B1 (en) 2004-08-27 2010-10-06 Cordis Corporation Solvent free amorphous rapamycin
US7582312B2 (en) * 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102164579B (zh) 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
EP2387400A1 (en) * 2009-01-15 2011-11-23 Cephalon, Inc. Novel forms of bendamustine free base
WO2011151704A2 (en) * 2010-06-02 2011-12-08 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of rapamycin esters
WO2013117969A1 (en) 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
CN102940630A (zh) * 2012-11-16 2013-02-27 浙江海正药业股份有限公司 含有西罗莫司酯化物的药物组合物及其制备方法
WO2014118696A2 (en) * 2013-01-29 2014-08-07 Gland Pharma Limited Pharmacuetical compositions of rapamycin esters and its derivatives
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
CN104510708B (zh) * 2013-09-29 2018-04-24 正大天晴药业集团股份有限公司 一种米铂冻干制剂及其制备方法
US10342769B2 (en) 2014-11-14 2019-07-09 Navinta Iii Inc Carmustine pharmaceutical composition
WO2017129772A1 (en) 2016-01-29 2017-08-03 Xellia Phamaceuticals Aps Stable pharmaceutical compositions of temsirolimus
CN105687132B (zh) * 2016-03-17 2020-06-12 鲁南贝特制药有限公司 一种坦西莫司注射用浓溶液及其制备方法
CN107773539A (zh) * 2016-08-27 2018-03-09 鲁南制药集团股份有限公司 一种注射用坦西莫司及其制备方法
CN111165656A (zh) * 2020-01-09 2020-05-19 南京大学（溧水）生态环境研究院 一种黑水虻冻干粉高效制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204775B (it) * 1986-01-31 1989-03-10 Rosella Silvestrini Kit per la determinazione dell'attivita' proliferativa nei tumori umani
US5352783A (en) * 1993-06-09 1994-10-04 Merck & Co., Inc. Microbial transformation product having immunosuppressive activity
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
ES2187660T3 (es) * 1995-06-09 2003-06-16 Novartis Ag Derivados de rapamicina.
GB9514594D0 (en) * 1995-07-17 1995-09-13 Johnson & Johnson Clin Diag Chemiluminescent analytical method
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
DE19936281C2 (de) * 1999-08-02 2002-04-04 Bayer Ag Verfahren zur Gefriertrocknung
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
GB0008785D0 (en) * 2000-04-10 2000-05-31 Novartis Ag Organic compounds
PT1318837E (pt) * 2000-08-11 2004-12-31 Wyeth Corp Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI307277B (en) * 2002-07-30 2009-03-11 Wyeth Corp Parenteral formulations
MXPA05002828A (es) * 2002-09-17 2005-05-27 Wyeth Corp Formulaciones orales.
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція

Also Published As

Publication number Publication date
TW200505501A (en) 2005-02-16
US20050020615A1 (en) 2005-01-27
KR20060052880A (ko) 2006-05-19
CA2532251A1 (en) 2005-02-10
NO20056178L (no) 2006-02-17
ECSP066394A (es) 2006-08-30
AU2004261163A1 (en) 2005-02-10
WO2005011688A1 (en) 2005-02-10
IL172573A0 (en) 2006-04-10
CR8153A (es) 2006-05-26
MXPA05013865A (es) 2006-02-28
AR045094A1 (es) 2005-10-12
EP1648454A1 (en) 2006-04-26
RU2345772C2 (ru) 2009-02-10
JP2007500191A (ja) 2007-01-11
RU2006105645A (ru) 2006-06-27
SG144165A1 (en) 2008-07-29
CO5680425A2 (es) 2006-09-29
ZA200600684B (en) 2008-07-30
CN1829514A (zh) 2006-09-06

Similar Documents

Publication Publication Date Title
BRPI0412916A (pt) formulações liofilizadas de cci-779
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
CY1116506T1 (el) Αντισωματα εναντι masp-2
EP1535907A4 (en) BENZOLSULFONATE OF A 4-FLUORO-2-CYANOPYRROLIDINE DERIVATIVE
BRPI0409185A (pt) formulações veterinárias anti-helmìnticas tópicas
WO2004038378A3 (en) Phthalocyanine dyes
CY1110780T1 (el) Τοπικα σκευασματα νεπαφενακης
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
BR0318278A (pt) compostos de éter aminocicloexìlico e usos dos mesmo
AR038568A1 (es) Anticuerpos anti-a beta y su uso
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
WO2004105722A8 (en) A formulation for chemical peeling
BR0208874A (pt) Proteìnas superficiais de streptococcus pyogenes
WO2005042560A3 (en) Non-viral delivery of compounds to mitochondria
FI20021184A7 (fi) Lignaanivalmisteita
WO2004080405A3 (en) Igf-binding protein-derived peptide or small molecule
IT1318319B1 (it) Composizione di gomma, procedimento per produrre la stessa e manicottoutilizzante la composizione di gomma.
WO2003063851A8 (en) Composition for pharmaceutical or dietetic use for combating hair loss
EP1423137A4 (en) Lipopeptide stereoisomers, methods for preparing same, and useful intermediates
WO2003025119A3 (en) Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
EP2292255A3 (de) Stabile therapeutische Proteine
AR043972A1 (es) Formulaciones farmaceuticas de fsh y lh
BR0312814A (pt) Levamisol / avermectinas ou similares em solvente de pirrolidona
WO2006042661A3 (en) Oligopeptides and their use in cosmetics

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.